# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Franklin D. Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET002-SYN-TD
- Date: 1944-03-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Brooks, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for primary care visit for breathlessness, orthopnea, and leg swelling. **S**

## Objective

NT-proBNP: 2850 pg/mL (high); Sodium: 137 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 1.18 mg/dL; eGFR: 70 mL/min/1.73 m²; Glucose: 104 mg/dL (high); Hemoglobin: 12.6 g/dL (low); Ferritin: 48 ng/mL; Transferrin saturation: 16% (low); TSH: 2.1 mIU/L; LDL cholesterol: 132 mg/dL (high); HbA1c: 5.9% (high); Urine albumin-creatinine ratio: 64 mg/g (high); KCCQ-12 overall summary: 38; PHQ-2: 1. All results are synthetic.

BP 186/108 mmHg; pulse 96 bpm; respirations 22/min; temperature 36.9 °C; oxygen saturation 93% on room air; weight 88 kg; BMI 24.9 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1862 findings; Heart failure with reduced ejection fraction, NYHA class III at diagnosis; Nicotine dependence, cigarettes; Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed; Prediabetes; Hyperlipidemia. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily **S**
- Started: Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food **S**
- Started: Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Started: Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Started: Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Started: Nicotine 21 mg/24 hr transdermal patch, apply one patch daily **S**

## Plan

- Start guideline-directed therapy for HFrEF: sacubitril/valsartan, carvedilol, and empagliflozin, with furosemide for congestion; add spironolactone after the two-week potassium check. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) **S**
- Check a basic metabolic panel one to two weeks after each renin-angiotensin or mineralocorticoid antagonist change, then every three to six months when stable. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026) **S**
- Treat to a blood pressure below 130/80 with home blood pressure and daily weight logs; low-sodium diet. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026) **S**
- Tobacco cessation counseling with nicotine replacement and a quit date. Guideline: Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**
- Cardiology referral to confirm the diagnosis, review the echocardiogram, and guide titration. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) **S**
